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Objectives: Most national standard therapeutic guidelines recommend a 52-week 
trastuzumab regimen for breast cancer treatment. In contrast, the Iranian national 
guideline (published by the Ministry of Health) recommends a nine-week regimen. We 
assessed the differences between current routine practice amongst Iranian specialists 
and the guidelines for trastuzumab treatment and HER2 receptor testing in breast 
cancer. MethOds: 128 Iranian hematology oncologists and radiotherapy oncologists 
were asked to complete an online anonymous questionnaire. Concurrently, a 3-year 
retrospective claims database analysis was conducted using data from the Social 
Security Organization, a health insurer which covers approximately 50% of the Iranian 
population, to enable comparisons with the questionnaire results. Results: With 
a 41% (52/128) response rate, doctors reported a relatively high absolute adherence 
(86%) to the guideline for HER2 receptor testing but a low rate of absolute adherence 
(6%) to the guideline for duration of trastuzumab treatment. Doctors indicated that 
the planned duration was 9 weeks in only 32% of patients; in most cases, the plan 
was 52-week treatment. Patients with a 9-week treatment plan received trastuzumab 
for 8.6 weeks on average while patients with 52-week plans received treatment for 
29.2 weeks. The general trends found in the survey were confirmed in the claims 
database analysis of 830 HER2 positive patients. cOnclusiOns: When it comes to 
trastuzumab use, Iranian doctors appear to rely more on the medical literature than 
on national guidelines developed by the Ministry of Health. Policymakers, doctors 
and the general public should try to reach some consensus about the optimal way to 
treat eligible patients. This is particularly necessary in low-middle income countries, 
whose limited budget cannot easily accommodate all of the innovative technologies 
to come. Inventive reimbursement policies may form part of the solution as long as 
the experiences from other countries are examined.
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Objectives: Trastuzumab (TRA) subcutaneous (SC) injection is an alternative to 
intravenous (IV) administration for the treatment of HER2+ early breast cancer (EBC). 
The objective was to quantify health care professional (HCP) time and patient chair 
time related to TRA treatment to estimate potential time and cost savings with a 
transition from IV to SC. MethOds: A multi-centre, prospective time-and-motion 
study was run in three Russian centres participating in the SafeHer clinical trial 
(MO28048). Case report forms listing pre-specified tasks for IV, SC, and pharmacy 
management in chronological order and tailored to site practices were used for data 
collection. Trained observers recorded patient chair time and durations that HCPs 
were actively completing the tasks. A random effects regression model was run for 
each task to generate mean and 95% confidence intervals. IV vs. SC process time was 
calculated as the sum of the mean task times. HCP and chair time were translated to 
cost using Russian salary data, and 354 roubles (p) per infusion chair hour. Results: 
Mean reduction in HCP time per patient session was 18.6min (-48%) (IV: 38.7min vs. 
SC: 20.1min; centre range: 8.6-31.1min), of which 61% of time reduced was achieved 
in the treatment room. Per treatment session (total 18 sessions), the estimated time 
saving was 5.6 hours (range across centres: 2.6-9.3hours). Reduction in mean chair 
time was 59.5min (-89%) (IV: 67.1min vs. SC: 7.6min; centre range: 29.8-97.3min). 
The monetary value of HCP and patient chair time saved was 1,175p and 6,314p, 
respectively, for 18 treatment sessions. cOnclusiOns: Transition from IV to SC TRA 
leads to substantial reductions in administration chair time, active HCP time and 
associated costs. This allows more time to be used for other patient care activities, 
increasing the number of patients who could be treated and thus increasing the 
overall efficiency of treatment centers.
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Objectives: The present study aimed to examine how breast cancer patients 
proceed through the public Greek health care system by using process mapping to 
identify constraints and bottlenecks and unnecessary process steps. MethOds: 
The sample of the study were 86 patients diagnosed with breast cancer at two 
large public oncological hospitals. A process mapping study, by applying PERT 
(Program Evaluation Review Technique) analysis, was conducted. Results: The 
total time spent for obtaining the treatment (per os or chemotherapy) is higher up 
to 7 times compared with the time spent in activities contributing directly towards 
the patient’s outcome. The average time needed to complete the procedure (e.g. 
physician consultation, waiting times, prescribing, obtaining pharmaceuticals) 
in Hospital A was 78.65 minutes (SD= 37.43) while waiting time was 51 minutes 
(64.9%). In Hospital B the respective time was 101 min (SD= 50.54) and 83.1% of that 
time was the waiting time. Similarly, the average time required for chemotherapy 
at Hospital A was 4 hours and 27 minutes (SD= 106.61) while the waiting time was 
2 hours and 15 minutes (50.8%). In Hospital B, the average time for chemotherapy 
was 3 hours 35 minutes (SD= 69.49) and 52.2% of that time was the waiting time. 
Among the main reasons for the delays were the lack of electronic records and 
poor function of the Central Information Prescribing System. cOnclusiOns: 
Waiting time represented the higher percentage of the total time needed to com-
plete the process for obtaining the treatment. As it represents one of the major 
causes for patient dissatisfaction, applying process mapping is a critical step for 
health care organizations to improve the beneficial time and the overall quality 
of the services offered.
0.2% (pancreas cancer) to 16.6% leukemia for females. Inconsistent changes were 
noticed for either incidence or mortality of different cancers. There were no sta-
tistically significant correlations between change in 5-year survival, and change 
in incidence and mortality for either male or female cancers during this period. 
When other time periods were considered for analysis, statistically significant 
correlations were noticed between change in 5-year survival and incidence of 
male cancers from 1981 to 1995 (Pearson r= 0.68; P= 0.03) and from 1986 to 1995 
(Pearson r= 0.78; P= 0.007). However, when the two mostly overdiagnosed cancers 
(prostate and breast) were excluded, there were no correlations between change 
in 5-year survival, and change in incidence and mortality for the three time peri-
ods. cOnclusiOns: Our study shows no reliable relationships between changes 
in 5-year survival and incidence or mortality. The increase in 5-year survival might 
not represent progress in cancer control, but instead indicate improved diagnosis 
and treatment in clinical practice.
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Objectives: Pilot study for evaluation of record linking and potential analysis of 
combination of epidemiologic cancer registry data and personalized pathway of 
care identified by billing data using lung cancer as test illness for Austrian data-
sets in the years 2006 till 2011. MethOds: Data sets are linked by anonymized 
distinct social insurance numbers of approximately 85 percent of all detected 
incident lung cancer patients in Austria in the years 2006 till 2011 with billing 
data on single person level. The calculated dataset deals as starting point for the 
analysis of the remaining lifetime distribution depending on age and TNM – state. 
Analysis of care classified by eight main categories given in hospitals coded by the 
MEL-system in combination with treatment using defined drugs is analysed and 
reported for further interpretation by the experts. An exploratory data analysis on 
the socio-economic standard and regional differences in Austrian federal states 
complete the pilot study. Results: Data for the whole Austrian health insured 
population, including incident cases for lung cancer over a time span of two years 
were analysed for the following chronic diseases detected by predefined rules 
on hospital diagnoses and drug prescription in the one year preceding patient 
history: COPD, diabetes and psychiatric illnesses. For the detected 6616 patients 
the probability of surviving is calculated and visualized by Kaplan-Meier-Curves. 
Exemplarily the one year survival is given: 75,44% and the 3-years life expectancy: 
~1% Further results combining different influence factors on survival including 
data from the cancer registry information table are performed. cOnclusiOns: 
Combining data collected by the national epidemiological cancer registry system 
and personalized pathways of patient treatment in intramural and extramural care 
provides a broad basis for analysis concerning real world pathway comparison 
of cancer patients. This work can unlock potential in respect of defining clinical 
national cancer registries.
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Objectives: Clinical oncology societies develop and regularly update evidence-
based guidelines in order to achieve more reliable and updated tools for patient 
management. In 2004 AIOM (Italian Association of Medical Oncology) created the 
RIGHT program: Research for the Identification of the most effective and hIGHly 
accepted clinical guidelines for cancer Treatment. It aims to evaluate the concord-
ance between AIOM breast (BC), colorectal (CRC) and lung (LC) cancer guidelines 
and clinical practice in Italian cancer centers. MethOds: the RIGHT program is 
composed by three retrospective observational studies, one for each guideline, 
conducted in a sample of 35 (BC) +37 (CRC) +53 (LC) Italian centers for cancer 
care representative of 230 AIOM centers. Site sampling from AIOM database was 
stratified by geographic distribution (North, Center, South). Indicators were iden-
tified to verify the concordance between AIOM guidelines and clinical practice 
about staging and treatment. Patients were included if they had their first visit 
at the site after guideline emission. Patients were then followed-up for at least 
6 months. Results: Patients enrolled for the breast, colorectal and lung cancer 
guideline evaluation were 324, 326, and 708, respectively. Adherence was on aver-
age 69% for BC, 76% for CRC and 69% for LC. For CRC adherence was 78% for colon, 
69% for rectal cancer and 83% for advanced disease. For BC, the lowest degree 
of compliance (0%) was observed for the follow-up indicator in asymptomatic 
patients. For LC, on average 67%, 46% and 81% of stage I-II-IIIA, IIIB and IV patients 
respectively received recommended care according to defined lung cancer indi-
cators cOnclusiOns: The RIGHT program showed that guidelines adherence 
is generally high, with very few cases of low adhererence. Guidelines adherence 
monitoring and update represent crucial activity to get more useful instrument 
to plan health care interventions.
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currently used agents, strategies such as cost-sharing to encourage payers to think 
beyond the price tag, and promoting familiarity with novel agents among regional 
and local payers will help optimize the market access opportunity.
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Objectives: The objective of the analysis was to assess the pricing and reimburse-
ment possibilities, as well as the budget impact, of a new medicine for bladder 
cancer immunotherapy. MethOds: We investigated the number of medicines 
for bladder cancer immunotherapy that were registered and listed in the period 
between March 2011 and March 2014, in Serbia. We also made pharmacoeco-
nomics analysis that would be a part of the Health Insurance Fund submission 
file. Results: According to the European Association of Urology (EAU) Guidelines 
for non-muscle invasive bladder cancer (NMIBC) there are several bladder preser-
vation strategies available: intravesical immunotherapy, intravesical chemother-
apy, device-assisted therapy and combination therapy. In Serbia, there are three 
medicines listed for chemotherapy (doxorubicin, epirubicin and mitomycin) and 
one for intravesical immunotherapy (BCG). BCG has become the standard of care 
for high-grade NMIBC and carcinoma in-situ (CIS) and is superior to intravesical 
chemotherapy in reducing recurrences, in preventing or delaying progression of the 
disease. Radical cystectomy should be considered after BCG treatment failure, when 
BCG is contraindicated or not available. BCG is reimbursed in Serbia (wholesale 
price: 79,18€ ) but due to continuous shortages of registered BCG from May 2012, 
non-registered BCG was also listed (price: not defined). Still there was no import, 
due to worldwide shortages. The absence of the treatment encouraged the Serbian 
Institute of Virology, Vaccines and Sera “Torlak” to develop BCG for immunotherapy. 
As the price proposal for new medicine would be 55,43€ , expenses per patient per 
year would be 498,87€ and total costs for 520 patients would be 259.412,40€ , it is 
projected that total savings would be 111.150,00€ per year. Market share of domestic 
BCG would be 0,29% of total B list (hospital medicines) budget. cOnclusiOns: The 
future aim is to develop, register and list domestic BCG that would provide lower 
costs per patient, high quality, availability and the continuous immunotherapy.
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Objectives: To provide a better understanding of: how changes in the use of an 
oncology medicine can affect its aggregate value; how different HTA systems have 
assessed these value expansions; and whether there is a link between value expan-
sions and use. MethOds: We examine all oncology medicines approved by the 
EMA between 2003 and 2005 – giving a sample of 10 medicines. Our framework sets 
out seven possible value expansions beyond an initial approved indication: differ-
ent cancer type; different disease stage; different treatment line/stage; different 
treatment regimen; orphan designation; patient sub-population; and new route of 
administration. We then assessed how HAS (France), NICE (England and Wales), and 
Aetna (US) have recognised these value expansions. Finally, we analysed IMS data 
(2004-2013) on prices, volumes and sales for the five of the medicines. Results: 
Seven of the 10 medicines in the sample have additional value expansions following 
initial indication. Many are now used for indications that are very different from 
their original indication. Most of the HAS assessments resulted in the drug being 
reimbursed but the rewards to the manufacturers were in many cases relatively low 
because few of the recommended drugs were given low “improvement in medical 
service” (ASMR) levels. The majority of NICE appraisals (63%) resulted in the drug/
indication not being recommended for use in the NHS. Generally, the UK had lower 
prices, volumes and sales than France and the US (with some exceptions). The 
comparisons between France and the US were a little more equivocal. There is a 
mixed picture in terms of the correlation between NICE/HAS recommendations and 
sales in the UK/France. We observe a link between expansions in licensed indica-
tions and changes in sales. cOnclusiOns: Health systems and policy makers need 
to recognise how product life-cycle considerations affect the value of medicines, 
and in particular, oncology medicines.
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Objectives: In December 2011, a threshold value of costs/QALY was introduced 
to Slovak legislation. The aim of this work is to assess its impact on inclusion of 
oncology drugs to the reimbursement system and their availability in clinical 
practice. MethOds: We evaluated the inclusion of oncology drugs to the reim-
bursement system based on data from the website of the Ministry of Health SR. 
We analysed the consumption of drugs based on the National Health Information 
Centre database. We acquired information about registered oncology drugs on the 
EMA website. We determined the level of availability of oncology drugs in clini-
cal practice via a qualitative survey among oncologists. Results: The success 
rate of including new oncology drugs in Slovakia was high in 2000-2011. From the 
62 oncology drugs registered in this period by the EMA, 48 were included to the 
Reimbursement List. Innovative oncology drugs were included relatively quickly 
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Objectives: In recent years (2011-2014) various new oncology therapies were 
launched and evaluated by the different market access authorities. The interna-
tional Prismaccess database includes all evaluations and decisions by the respec-
tive authorities in France, Germany and the UK. MethOds: All decisions for new 
oncology therapies which were evaluated by the authorities in France, Germany 
and UK were systematically searched for. A comparison was executed with a 
focus on reimbursement decision, basis of decision, acceptance of submitted 
clinical endpoints, study designs, comparator, quality of life and indirect treat-
ment comparison (ITC). Results: In total there were 23 new oncology therapies 
being evaluated in the three countries. In France 10 decisions were positive (ASMR 
I-III), further 6 of minor improvement (ASMR IV), 20 were positive in Germany 
(n= 3 ‘significant’; n= 6 ‘considerable’; n= 9 ‘minor’; n= 2 ‘non-quantifiable’ added 
benefit) and 4 were positive in England and 5 in Scotland. In 2 cases, respectively 
the assessment was positive (different magnitude) or negative in all countries. 
26% (n= 6) it was similar in at least three countries. (n= 5 positive decisions; n= 1 
negative decision). In case overall survival was the primary endpoint the likeli-
hood was higher in all countries for a positive decision. Key differences in terms 
of decisions were given in acceptance of ITCs, comparator as standard of care and 
ratings for cost-effectiveness. cOnclusiOns: Using the Prismaccess database the 
analysis shows that there might be key differences in terms of evaluation criteria 
between the three countries analysed. In Germany a key focus is given on the 
appropriate comparator(s) and patient-relevant endpoints. In the UK and Scotland 
cost-effectiveness might trump a positive benefit assessment. In France the key 
drivers are not only the severity of the pathology (for tumours, 25% of SMR are not 
substantial), but also efficacy/adverse events ratio, Effective amount, Comparator 
choice and Therapeutic strategy.
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Objectives: Korean government has been making efforts to improve the access 
of orphan drugs or cancer drugs to patients since it is difficult for these drugs 
to be reimbursed due to its high price or lack of clinical evidence. We aim to 
investigate the current status of reimbursement and reviewed related schemes 
in Korea. MethOds: Appraisal results for orphan or cancer drugs during 7 years 
(2007~2013) were included and recommendation rate, final listing rate and order of 
entry among 8 countries were analyzed. Results:  Total 331 were recommended to 
be reimbursed in overall 467 appraisal results (71%), whereas 74 was recommended 
to be reimbursed among 121 results for orphan or cancer drugs (61%), indicating 
that it was less likely to be recommended for those drugs. Fifty eight orphan or 
cancer drugs (48%) were finally listed through NHIC negotiation process. For cancer 
drugs, recommendation and listing rate seem to increase from 47% to 64% and 32% 
to 48% (2008~2010 vs 2011~2013), respectively. Those drugs have been reimbursed 
in the 4.86th place among 8 countries including Korea on the average. Besides, 15 
drugs considered as rule of rescue in those drugs have been listed for reimburse-
ment. cOnclusiOns: We identified that orphan or cancer drugs has been more 
accessible to patients as time goes. As the benefit enhancement plan for four major 
diseases (2013) and the Risk Sharing scheme (2013) have been implemented, it is 
expected for the coverage for those drugs in Korean National Health Insurance to 
be widened through these schemes.
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Objectives: Health technology assessment (HTA), pricing and reimbursement 
(P&R) processes, and cost-containment strategies in France, Germany, Italy, Spain, 
and the UK, are increasingly stringent. This study explored the resulting impact on 
high-cost oncology brands, and carved out specific market access levers and barri-
ers. MethOds: Across the EU5, 500 medical or hematological oncologists were sur-
veyed regarding their current and expected prescribing patterns, and 30 payers who 
influence reimbursement at national or regional level were interviewed. Results: 
Some 68-83% of surveyed oncologists in France, Italy, Spain, and the UK, and 44% 
in Germany report that the average time taken by their health care authority to 
review newly approved cancer treatments and settle reimbursement terms delays 
availability for prescribing by ≥ 6 months. Thereafter, country-specific prescribing 
restrictions impede uptake; e.g., 18% of German hematologists surveyed report 
that their indicative prescribing budget prevents use of ponatinib in > 20% of their 
chronic myeloid leukemia patients, while 30% of Italian medical oncologists say the 
national oncology drugs register monitoring use of costly agents severely restricts 
prescribing of erlotinib and gefitinib for non-small-cell lung cancer. Interviewed 
payers stress, however, that well-designed pivotal trials considering increasing focus 
on added benefit over direct comparators will help optimize HTA and P&R terms, 
with those in Italy and the UK, especially, advocating cost-sharing schemes to secure 
market entry. Furthermore, demonstrable downstream cost savings, locally targeted 
marketing campaigns, and manufacturer estimates of patient population size to aid 
regional/local budget planning are specified as uptake levers. cOnclusiOns: HTA 
and P&R demands and tightening budgets negatively impact prescribing of costly 
oncology brands in the EU5. However, clear demonstration of robust benefits over 
